Clinical Trial: Effects of Timing of Peripheral Nerve Block and Dexamethasone as an Adjuvant on Postoperative Analgesia after Thoracic Surgery (Japan)

Tokyo, Sept. 5 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062826) titled 'Effects of Paravertebral Block Timing and Dexamethasone as an Adjuvant on Postoperative Analgesia After Thoracoscopic Surgery: A Randomized Single-Blind 2x2 Factorial Trial' on Sept. 4.

Study Type: Interventional

Study Design: Basic Design - Factorial Randomization - Randomized Blinding - Single blind -participants are blinded Control - No treatment

Primary Sponsor: Institute - Gifu University

Condition: Condition - Acute postoperative pain after thoracoscopic surgery for lung cancer, mediastinal tumors, and other thoracic diseases Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - The objective of this study is to determine whether the addition of dexamethasone to ropivacaine for paravertebral block prolongs postoperative analgesia and reduces rebound pain in patients undergoing thoracoscopic surgery. The study also aims to compare the analgesic effects of paravertebral block performed before versus after surgery and to identify an optimal perioperative analgesic strategy for thoracic surgery. Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - Paravertebral block is performed before surgery using 30 mL of 0.3% ropivacaine without dexamethasone. Interventions/Control_2 - Paravertebral block is performed before surgery using 30 mL of 0.3% ropivacaine with 3.3 mg of dexamethasone.

Eligibility: Age-lower limit - 18 years-old = Gender - Male and Female Key inclusion criteria - Patients aged 18 to 75 years undergoing unilateral thoracoscopic surgery at Gifu University Hospital. Patients with American Society of Anesthesiologists Physical Status (ASA-PS) 1-3. Patients who provide written informed consent to participate in the study. Key exclusion criteria - Patients with severe coagulation abnormalities. Patients with a body mass index of 35 kg/m2 or greater. Patients with diabetes mellitus and a random blood glucose level of 200 mg/dL or greater, or an HbA1c level of 7.3% or greater. Patients with chronic pain currently requiring treatment. Patients already receiving opioid analgesic therapy. Patients unable to complete the study questionnaires. Patients with cognitive impairment. Patients considered inappropriate for participation by the investigator. Target Size - 200

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2026 Year 03 Month 20 Day Date of IRB - 2026 Year 03 Month 24 Day Anticipated trial start date - 2026 Year 10 Month 01 Day Last follow-up date - 2029 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071913

Disclaimer: Curated by HT Syndication.